FY2024 Earnings Forecast for HOWL Issued By Leerink Partnrs

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) – Investment analysts at Leerink Partnrs raised their FY2024 earnings per share (EPS) estimates for shares of Werewolf Therapeutics in a research report issued to clients and investors on Monday, November 11th. Leerink Partnrs analyst D. Graybosch now anticipates that the company will post earnings per share of ($1.98) for the year, up from their previous estimate of ($2.07). The consensus estimate for Werewolf Therapeutics’ current full-year earnings is ($1.56) per share. Leerink Partnrs also issued estimates for Werewolf Therapeutics’ Q4 2024 earnings at ($0.80) EPS, Q1 2025 earnings at ($1.17) EPS, Q2 2025 earnings at ($1.22) EPS, Q3 2025 earnings at ($0.99) EPS, Q4 2025 earnings at ($0.86) EPS, FY2025 earnings at ($4.15) EPS, FY2026 earnings at ($3.40) EPS, FY2027 earnings at ($2.98) EPS and FY2028 earnings at ($2.56) EPS.

Werewolf Therapeutics Stock Down 4.7 %

Shares of NASDAQ:HOWL opened at $2.05 on Wednesday. The company has a market capitalization of $91.35 million, a price-to-earnings ratio of -1.34 and a beta of 0.41. The company has a 50 day moving average of $2.27 and a two-hundred day moving average of $2.93. Werewolf Therapeutics has a 52-week low of $1.66 and a 52-week high of $8.19. The company has a quick ratio of 10.10, a current ratio of 10.10 and a debt-to-equity ratio of 0.29.

Institutional Investors Weigh In On Werewolf Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Millennium Management LLC boosted its position in Werewolf Therapeutics by 96.4% in the 2nd quarter. Millennium Management LLC now owns 1,110,298 shares of the company’s stock valued at $2,709,000 after buying an additional 544,881 shares during the last quarter. Janus Henderson Group PLC purchased a new position in Werewolf Therapeutics in the first quarter valued at about $10,922,000. Acadian Asset Management LLC grew its stake in Werewolf Therapeutics by 119.8% during the 1st quarter. Acadian Asset Management LLC now owns 172,883 shares of the company’s stock valued at $1,119,000 after purchasing an additional 94,212 shares in the last quarter. Vanguard Group Inc. increased its holdings in Werewolf Therapeutics by 26.8% during the 1st quarter. Vanguard Group Inc. now owns 1,107,347 shares of the company’s stock worth $7,176,000 after purchasing an additional 233,909 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of Werewolf Therapeutics by 103.1% in the 2nd quarter. Renaissance Technologies LLC now owns 171,000 shares of the company’s stock valued at $417,000 after purchasing an additional 86,800 shares in the last quarter. 64.84% of the stock is owned by institutional investors and hedge funds.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.